Detailed price information for Humana Inc (HUM-N) from The Globe and Mail including charting and trades.
The latest valuation work on Humana lifts the assessed fair value from US$465.13 to US$475.54, signaling a modest reset in price targets. Analysts linking this move to recent Q3 results and improved Medicare Advantage Star Ratings describe a generally constructive mood, even as some still flag policy and execution risks. Read on to see what is driving the shifting Humana story and how you can track the next turns in this narrative. Analyst Price Targets don't always capture the full story...
Humana (HUM) stock jumps as the company posts better-than-expected Q3 2026 results and raises its full-year outlook thanks mainly to its CenterWell unit. Read more here.
Humana reported a third-quarter net income of $162 million as care costs for older adults in Medicare Advantage plans rose.
Detailed price information for Humana Inc (HUM-N) from The Globe and Mail including charting and trades.
LOUISVILLE, Ky., November 06, 2026--Humana Inc. (NYSE: HUM) today reported consolidated pretax results and diluted earnings per share for the quarter ended September 30, 2026 (3Q26) versus the quarter ended September 30, 2025 (3Q25) and for the nine months ended September 30, 2026 (YTD 2026) versus the nine months ended September 30, 2025 (YTD 2025) as noted in the tables below.
This is the newest page. Registered accounts read further back.